According to the American Diabetes Association (ADA)/ European Association for the Study of Diabetes (EASD) guideline, a patient-centered approach to type 2 diabetes (T2D) management should be adopted with the goal of not only preventing complications but also optimizing patients’ quality of life.¹ To achieve these goals, factors that affect health-related quality of life (HRQoL) such as social determinants of health, psychosocial well-being, and health behaviors are key considerations in glycemic management strategies for patients with T2D.¹ At the EASD Annual Meeting 2023, Professor Chan, Chung-Ngor Juliana from the Department of Medicine and Therapeutics, The Chinese University of Hong Kong presented the results of a cross-sectional analysis of HRQoL in patients with T2D treated with oral glucose-lowering drugs (OGLDs) who were enrolled in the Joint Asia Diabetes Evaluation (JADE) Register. In a subsequent interview with Omnihealth Practice, Prof. Chan shared further insights on the application of the JADE® Program, shedding light on the dynamics between glycemic management strategies and patients’ HRQoL.

Heart failure (HF) is global pandemic affecting at least 26 million people worldwide in 2017 and has been increasing in prevalence.¹ In 2020, HF plus other heart diseases caused an age-standardized death rate of 34.0 per 100,000 standard population in Hong Kong.² Previously, patients with HF with reduced ejection fraction (HFrEF) were treated with a foundational triple therapy including β-blockers, renin-angiotensin system inhibitors [including angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)] or angiotensin receptor-neprilysin inhibitors (ARNIs), as well as mineralocorticoid receptor antagonists (MRAs).³ With reference to the recent data supporting the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in patients with chronic HFrEF regardless of the diabetes status, it is noted that comprehensive diseasemodifying quadruple therapy has now become the new standard of care for HFrEF patients.^4,5 In a recent interview with Omnihealth Practice, Professor Siu, Chung-Wah David shared his insights on the application of SGLT2i in HFrEF treatment.

Fragility fractures are increasingly recognized as a relevant complication of both type 1 and 2 diabetes mellitus (T1DM/T2DM).1 Compared to the general population, T1DM and T2DM patients have a significantly higher fracture risk in both males and females at all ages with the difference increasing fu

Weight control remains an indispensable component for the clinical management of type 2 diabetes mellitus (T2DM) in preventing cardiometabolic morbidity.1-3 People with T2DM who received weekly subcutaneous injection of semaglutide 2.4mg achieved superior and clinically meaningful reduction of body

The prevalence of diabetes has been rising both locally and globally, with 400 million people affected worldwide and over half being Asians.1 For type 2 diabetes mellitus (T2DM), industrialization and urbanization are known to be the risk factors associated with obesity and overweight in all age gro

While they may not necessarily have a causal relationship, both chronic kidney disease (CKD) and diabetes mellitus (DM) have become increasingly more prevalent worldwide.1 As these conditions could be risk factors for developing acute kidney injury (AKI),2 CKD and DM must be carefully managed to pre

Previous pandemics caused by severe acute respiratory syndrome (SARS), H1N1 influenza, and Middle East respiratory syndrome (MERS) are known to cause more severe symptoms in diabetic patients.¹ Similarly, in the recent epidemiological studies, diabetes has been consistently

More recently, a strategy of dual pathway antithrombotic therapy with antiplatelet and a reduced dose of anticoagulant has been tested and shown to be effective. The COMPASS trial demonstrated that aspirin plus rivaroxaban 2.5mg twice daily was superior to placebo for the reduction of ischemic event

Ever since the United States Food and Drug Administration (FDA) issued the mandate for conducting cardiovascular outcomes trials (CVOTs) with type 2 diabetes drugs, eight CVOTs have already been completed,

The idea of combining glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist for reducing glycated hemoglobin A_1c (HbA_1c) and body weight has already been circulated for quite some time.¹